Smith R M, Curnutte J T, Mayo L A, Babior B M
Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, La Jolla, California 92037.
J Biol Chem. 1989 Jul 25;264(21):12243-8.
The respiratory burst oxidase of neutrophils can be activated in a cell-free system in which solubilized membranes, cytosol, and Mg2+ are required and in which sodium dodecyl sulfate is used to convert the dormant oxidase to an active form. The 2',3'-dialdehyde analog of NADPH was used as an affinity label for the cytosolic NADPH binding component of the respiratory burst oxidase from human neutrophils. When treated with this affinity label in the presence of sodium cyanoborohydride to reduce Schiff bases, neutrophil cytosol was shown to lose at least 90% of its activity in the cell-free system. In contrast to normal cytosol, treated cytosol had lost its ability to abolish the lag time required for activation of the oxidase, suggesting that the treated cytosol was no longer able to participate in the rate-limiting activation step. Furthermore, the treated cytosol had lost its ability to convert the oxidase from a form with a high Km to a form with a low Km for NADPH. The ability of dialdehyde-treated cytosol to activate the oxidase could be restored by untreated cytosol with a concentration dependence suggesting that only one kinetically active component of the oxidase was inhibited by treatment with the NADPH analog. Like the dialdehyde-treated cytosol, cytosols from patients with chronic granulomatous disease caused by a deficiency in a cytosolic Mr = 47,000 protein (pp47) fail to participate in the rate-limiting activation step (Curnutte, J. T., Scott, P. J., and Babior, B. M. (1989) J. Clin. Invest. 83, 1236-1240). These chronic granulomatous disease cytosols were nevertheless able to restore limited activity to the dialdehyde-inactivated cytosol in a cell-free activation system. These results are consistent with a model in which (a) the NADPH binding subunit of the oxidase exists in a very slowly dissociating complex with one or more additional cytosolic components, including pp47, and (b) the NADPH binding component of the oxidase controls the affinity of the enzyme for NADPH, either directly or through the binding of additional cytosolic factors.
中性粒细胞的呼吸爆发氧化酶可在无细胞系统中被激活,该系统需要可溶性膜、胞质溶胶和Mg2+,并使用十二烷基硫酸钠将休眠的氧化酶转化为活性形式。NADPH的2',3'-二醛类似物被用作人中性粒细胞呼吸爆发氧化酶胞质溶胶NADPH结合成分的亲和标记。当在氰基硼氢化钠存在下用这种亲和标记处理以还原席夫碱时,中性粒细胞胞质溶胶在无细胞系统中显示至少丧失其90%的活性。与正常胞质溶胶相反,经处理的胞质溶胶失去了消除氧化酶激活所需滞后时间的能力,这表明经处理的胞质溶胶不再能够参与限速激活步骤。此外,经处理的胞质溶胶失去了将氧化酶从对NADPH具有高Km的形式转化为具有低Km的形式的能力。经二醛处理的胞质溶胶激活氧化酶的能力可通过未处理的胞质溶胶恢复,且具有浓度依赖性,这表明用NADPH类似物处理仅抑制了氧化酶的一种动力学活性成分。与经二醛处理的胞质溶胶一样,由胞质溶胶中分子量为47,000的蛋白质(pp47)缺乏引起的慢性肉芽肿病患者的胞质溶胶也无法参与限速激活步骤(Curnutte, J. T., Scott, P. J., and Babior, B. M. (1989) J. Clin. Invest. 83, 1236 - 1240)。然而,这些慢性肉芽肿病胞质溶胶能够在无细胞激活系统中为经二醛失活的胞质溶胶恢复有限的活性。这些结果与一个模型一致,在该模型中:(a)氧化酶的NADPH结合亚基与一种或多种其他胞质成分(包括pp47)以非常缓慢解离的复合物形式存在;(b)氧化酶的NADPH结合成分直接或通过结合其他胞质因子来控制酶对NADPH的亲和力。